A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks in patients with type 2 diabetes mellitus and insufficient glycaemic control despite metformin treatment.

Register Today!

Trial Information

Start DateCompleted
Trial Duration5 years +
Number of VisitsVariable
Lead CRCJessica Richer
End DateTBD

For additional information
on this trial contact: